【摘 要】
：
The use of goserelin in premenopausal patients is to produce castrated level of estradiol (E2), and the remaining peripheral E2 production is inhibited by letrozole, which would accomplish comparable
【机 构】
：
Center for Breast Cancer National Cancer Center (NCC) Korea
【出 处】
：
BIT‘s2nd Annual World Cancer Congess-2009 (2009第二届癌症大会)
论文部分内容阅读
The use of goserelin in premenopausal patients is to produce castrated level of estradiol (E2), and the remaining peripheral E2 production is inhibited by letrozole, which would accomplish comparable clinical outcomes as in post-menopausal metastatic breast cancer (MBC) patients (pts) by letrozole alone.Letrozole 2.5mg once a day was administered in premenopausal pts and letrozole with goserelin 3.6mg every 4 weeks in premenopausal pts.Serial serum E2, FSH, LH were measured.Bone mineral density (BMD), serum bone turnover markers were checked.
其他文献
It has long been known that excessive mitotic activity due to H-Ras can block keratinocyte differentiation and cause skin cancer.It is not clear whether there are any innate surveillants that are able
Tumor metastasis is a major reason for treatment failure in cancer patients.Melanoma is one of the types of cancer that most frequently metastasize, especially in the lung, but also in other organs.Cu
Standardisation and external quality controls are part of the routine in clinical biochemistry since years.International standards and external quality control rounds are absolutely warranted for any
In the past decades, the incidence of melanoma has risen steadily.Due to prevention efforts, the numbers seem to stabilize in younger age groups.Early diagnosis has increased the proportion of thin me
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lyrnphoma in North America.Response rate of DLBCL to the current empirically developed chemotherapy is only 50-60%.The need for dev
Uveal melanoma is the most common primary intraocular tumor in adults.Despite the advances in diagnosis and treatment of this tumor through the last decades, the mortality rates did not improved consi
Pancreatic cancer, called the silent killer, is the fourth leading cause of cancer-related death in both men and women in US.Due to difficulties in diagnosis and resistance to chemotherapy as well as
Pancreatic adenocarcinoma is among the most aggressive solid malignancies, being the 4th and 6th leading cause of cancer death in the United States and China respectively.Despite its rising incidence,
Accumulating evidences suggest that tumors are composed of a heterogeneous cell population with a small subset of cancer stem cells (CSCs) that sustain tumor formation and growth.Recently, there have
Background: Almost 60% of the patients with Acute Myeloid Leukemia (AML) are over the age of 60 years.Age is one of the strongest adverse prognostic factors for AML, both for induction remission and f